Clinical Trials Search
Clinical Trial 20825
Cancer Type: Gastrointestinal Tumor
Study Type: Treatment
NCT#: NCT04526106
Phase: Phase I
Prinicipal Investigator: Richard Kim
Study Title
A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors
Summary
This is an open-label, FIH study designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-4008, a potent and highly selective fibroblast growth factor receptor 2 (FGFR2) inhibitor administered orally patients with unresectable or metastatic ICC and other unresectable or metastatic solid tumors. This study consists of 2 parts, a dose escalation (Part 1) and a dose expansion (Part 2).
Objective
To determine the MTD and RP2D of RLY-4008 To determine the safety and tolerability of RLY-4008
Therapies
Medications
RLY-4008 ()
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.